RVX Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Resverlogix (TSE: RVX)
›
Resverlogix (TSE: RVX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0750 CAD on 19 November 2026, down 31.8% over 52 weeks. Its 52-week range is 0.0700 CAD to 0.1500 CAD: the price is 50.0% below the high and 7.1% above the low.
Its market capitalisation is 25.82M CAD.
Resverlogix reports return on equity of 8.7% and an operating margin of 0.0%.
Its debt exceeds its cash by 91.37M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.